Keep it short so you will use it
As strength and power decline with age, patients and providers fear going on GLP-1s as trading obesity risk for early frailty
In December 2024 , the FDA issued warning letters to Prime Peptides, Xcel Peptides, SwissChems, and Summit Research for selling semaglutide, tirzepatide, and retatrutide as unapproved drugs, part of a major escalating enforcement campaign against grey-market peptide vendors that has resulted in warehouse raids, criminal prosecutions, and multiple vendor shutdowns across 2025 and into 2026
Clinics should not be offering it as an approved treatment
Safety of supplementation of Omega-3 polyunsaturated fatty acids: a systematic review and Meta-analysis of randomized controlled trials
the most marketed supplements include NAM, NMN, and NR